Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SentoClone vs Reference Treatment in Advanced Malignant Melanoma
NCT00991250Phase 2Unknown
- Sponsor
- SentoClone International AB
- Start
- Oct 2009
- Primary completion
- Sep 2011
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of SentoClone in Malignant Melanoma (MM), sponsored by SentoClone International AB. Status: unknown.
02
Drugs
SentoClone
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00991250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991250.